Skip to Main Content

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM)

Conditions

Diseases of the Cardiovascular System

Phase III

What is the purpose of this trial?

Brief Summary:

Phase 3 efficacy and safety study to evaluate AG10 800 mg compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Trial with
    Eidos Therapeutics, Inc.
  • Start Date
    04/28/2019
  • End Date
    11/29/2022
Trial Image

For more information about this study, contact:

Nancy Hinchion

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/02/2019
  • Study HIC
    #2000025137